ABP-102 / CT-P72
HER2-positive cancers
PreclinicalActive
Key Facts
About Abpro
Abpro is a US-based biotech company founded in 2007, specializing in antibody discovery and engineering. It has transitioned to a publicly traded entity and is advancing a pipeline of bispecific and multispecific antibody candidates, with a lead T-cell engager program, ABP-102/CT-P72, in preclinical development for HER2-positive cancers. The company's strategy relies on its proprietary technology platforms and strategic collaborations, such as with Celltrion, to develop potential best-in-class therapies.
View full company profileTherapeutic Areas
Other HER2-positive cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| ES2B-C001 | ExpreS2ion Biotechnologies | Phase 1 |